CP
BDTX icon

Castleview Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Castleview Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-63,866
Closed -$324K – 924
2024
Q1 		$324K Buy
+63,866
New +$258K 0.18% 130

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleview Partners's BDTX Position: Q2 2024 in Review

Castleview Partners sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 63,866 shares — an estimated $324K sold.

Castleview Partners first reported a position in BDTX in Q1 2024 and held it in 1 quarter. The position peaked at $324K in Q1 2024. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • Castleview Partners reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Castleview Partners sold 63,866 Black Diamond Therapeutics shares in Q2 2024, an estimated $324K.
  • Castleview Partners first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 1 quarter.
  • Castleview Partners's Black Diamond Therapeutics position peaked at $324K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on Castleview Partners's 13F filing for Q2 2024, filed 31 Jul 2024.